A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

Lacosamide (MOTPOLY XR)

indicated for: Treatment of partial-onset seizures in patients 4 years of age and older (1.1) Adjunctive therapy in the treatment of primary generalized tonic-clonic seizures in patients 4 years of....

First FDA approval2009-05-26
Generic availableYes · 28 mfrs
Shortage statusNone
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one

$252.2M in CY2024 Part D spend1.4M claims · 243K beneficiaries · 329 plans surveyed

Lowest NADAC
$0.095/unit
20 NDCs benchmarked, lowest of all strengths.
Average NADAC
$0.101
Across all dosage forms in distribution.
Highest NADAC
$0.108
Range is tight.
Plans with PA
12 / 329
Limited PA friction.

Questions a plan sponsor actually asks.

FAQPage schema11 entries indexed · 4 visible
What is Lacosamide used for?

indicated for: Treatment of partial-onset seizures in patients 4 years of age and older (1.1) Adjunctive therapy in the treatment of primary generalized tonic-clonic seizures in patients 4 years of....

Is there a generic for Lacosamide?

Yes. 71 ANDAs filed at FDA, 28 generic manufacturers currently shipping.

How much does my plan pay for Lacosamide?

Across 329 Part D plans, Lacosamide averages $0.101/unit (NADAC). Lowest available: $0.095/unit. Highest in distribution: $0.108/unit.

Is Lacosamide on the FDA shortage list?

No. Lacosamide is not currently on the FDA Drug Shortage Database.

7 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Same class. Different math.

Anticonvulsant2 alternatives in D1
01
Levetiracetam
Brand: Keppra
$0.030Lowest NADAC
52Generic mfrs
$384.3MCY24 Part D spend
Compare →
02
Topiramate
Brand: Eprontia
$0.026Lowest NADAC
23Generic mfrs
$193.8MCY24 Part D spend
Compare →

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (10 approvals on file) · NADAC unit costs: CMS NADAC weekly file (20 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.